International Clinical Trial: A Trial to Compare the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered Using Two Subcutaneous Presentations

Geneva, Jan. 12 -- International Clinical Trials Registry received information related to the study (NCT07313761) titled 'A Trial to Compare the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered Using Two Subcutaneous Presentations' on Dec. 19, 2025.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Amgen

Condition: Overweight and Obesity

Intervention: Drug: Maridebart Cafraglutide

Recruitment Status: Not recruiting

Phase: Phase 1

Date of First Enrollment: December 15, 2025

Target Sample Size: 340

To know more, visit https://clinicaltrials.gov/stud...